CY1115604T1 - Μακροκυκλικα παραγωγα ουριας και σουλφαμιδης ως αναστολεις των ταfια - Google Patents

Μακροκυκλικα παραγωγα ουριας και σουλφαμιδης ως αναστολεις των ταfια

Info

Publication number
CY1115604T1
CY1115604T1 CY20141100631T CY141100631T CY1115604T1 CY 1115604 T1 CY1115604 T1 CY 1115604T1 CY 20141100631 T CY20141100631 T CY 20141100631T CY 141100631 T CY141100631 T CY 141100631T CY 1115604 T1 CY1115604 T1 CY 1115604T1
Authority
CY
Cyprus
Prior art keywords
inhibitors
sulfamidis
urine
safety
macrocyclic products
Prior art date
Application number
CY20141100631T
Other languages
English (en)
Inventor
Christopher Kallus
Mark Broenstrup
Andreas Evers
Anja Globisch
Herman Schreuder
Michael Wagner
Original Assignee
Sanofi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi filed Critical Sanofi
Publication of CY1115604T1 publication Critical patent/CY1115604T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D273/00—Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00
    • C07D273/01—Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00 having one nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D273/00—Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00
    • C07D273/02—Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00 having two nitrogen atoms and only one oxygen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

Η εφεύρεση αφορά ενώσεις του τύπου (Ι), οι οποίες είναι αναστολείς ενεργοποιημένων αναστολέων ινωδόλυσης που ενεργοποιούνται μέσω της θρομβίνης. Οι ενώσεις του τύπου (Ι) είναι κατάλληλες για την παρασκευή φαρμάκων για την πρόληψη, και θεραπεία μίας ή περισσοτέρων ασθενειών, οι οποίες συνοδεύονται από θρομβώσεις, εμβολές, υπερπηξία ή ινώδεις μεταβολές.
CY20141100631T 2008-06-06 2014-08-08 Μακροκυκλικα παραγωγα ουριας και σουλφαμιδης ως αναστολεις των ταfια CY1115604T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08290520 2008-06-06
EP09757185.5A EP2300462B1 (de) 2008-06-06 2009-05-22 Makrocyclische harnstoff- und sulfamidderivate als inhibitoren von tafia

Publications (1)

Publication Number Publication Date
CY1115604T1 true CY1115604T1 (el) 2017-01-04

Family

ID=39800716

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20141100631T CY1115604T1 (el) 2008-06-06 2014-08-08 Μακροκυκλικα παραγωγα ουριας και σουλφαμιδης ως αναστολεις των ταfια

Country Status (35)

Country Link
US (5) US8580777B2 (el)
EP (1) EP2300462B1 (el)
JP (1) JP5531011B2 (el)
KR (1) KR101673886B1 (el)
CN (1) CN102056922B (el)
AR (1) AR072007A1 (el)
AU (1) AU2009254257B2 (el)
BR (1) BRPI0913349A2 (el)
CA (1) CA2726554C (el)
CL (1) CL2009001358A1 (el)
CO (1) CO6321271A2 (el)
CR (1) CR11807A (el)
CY (1) CY1115604T1 (el)
DK (1) DK2300462T3 (el)
DO (1) DOP2010000363A (el)
EC (1) ECSP10010655A (el)
ES (1) ES2494390T3 (el)
HK (1) HK1152936A1 (el)
HN (1) HN2010002558A (el)
HR (1) HRP20140787T1 (el)
IL (1) IL209772A (el)
MA (1) MA32322B1 (el)
MX (1) MX2010012793A (el)
NI (1) NI201000203A (el)
NZ (1) NZ589671A (el)
PL (1) PL2300462T3 (el)
PT (1) PT2300462E (el)
RU (1) RU2502736C2 (el)
SI (1) SI2300462T1 (el)
SV (1) SV2010003747A (el)
TW (1) TWI455928B (el)
UA (1) UA104002C2 (el)
UY (1) UY31868A (el)
WO (1) WO2009146802A1 (el)
ZA (1) ZA201007719B (el)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5531011B2 (ja) 2008-06-06 2014-06-25 サノフイ ＴＡＦＩａの阻害剤としての大環状尿素およびスルファミド誘導体
BRPI0914323A2 (pt) 2008-06-23 2017-03-28 Astrazeneca Ab composto, formulação farmacêutica, uso de um composto, e, métodos de tratamento de uma condição e de tratamento e prevenção de distúrbios
US8354444B2 (en) 2008-09-18 2013-01-15 Hoffmann-La Roche Inc. Substituted pyrrolidine-2-carboxamides
EP2822953B9 (en) * 2012-03-06 2017-06-21 Pfizer Inc Macrocyclic derivatives for the treatment of proliferative diseases
AU2014280329A1 (en) * 2013-06-10 2016-01-07 Sanofi Macrocyclic urea derivatives as inhibitors of TAFIa, their preparation and their use as pharmaceuticals
UY35809A (es) * 2013-11-05 2015-05-29 Bayer Pharma AG (aza)piridopirazolopirimidinonas e indazolopirimidinonas y sus usos
CN103755852B (zh) * 2013-12-18 2015-12-09 湖北大学 线型聚苯乙烯支载(4s)-(4’-氧苄基)-2-正丁基环磺酰胺及其制备方法和用途
CN106631832A (zh) * 2016-10-08 2017-05-10 帕潘纳(北京)科技有限公司 一种氨基醚类化合物的制备方法
US10411291B2 (en) * 2017-03-22 2019-09-10 Nanotek Instruments, Inc. Multivalent metal ion battery having a cathode layer of protected graphitic carbon and manufacturing method

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU667995B2 (en) 1993-02-15 1996-04-18 Bayer Aktiengesellschaft New pseudopeptides having an antiviral action
TW394760B (en) 1993-09-07 2000-06-21 Hoffmann La Roche Novel Carboxamides, process for their preparation and pharmaceutical composition containing the same
US5888971A (en) * 1996-02-20 1999-03-30 Ortho Pharmaceutical Corporation, Inc. Macrocyclic peptides useful in the treatment of thrombin related disorders
DE69824433D1 (en) 1997-08-28 2004-07-15 Biovitrum Ab Proteintyrosinphosphatase inhibitoren
US6124278A (en) * 1998-04-03 2000-09-26 The Regents Of The University Of California Acylbenzoxazines for enhancing synaptic response
US6482921B1 (en) 1999-01-28 2002-11-19 Essential Therapeutics, Inc. Uridyl peptide antibiotic (UPA) derivatives, their synthesis and use
EP1130022B1 (en) * 2000-02-29 2009-07-22 Universita Degli Studi di Firenze 3-Aza-6,8-dioxabicyclo[3.2.1]octanes and analogues and combinatorial libraries containing them
DE102004020186A1 (de) * 2004-04-22 2005-11-17 Aventis Pharma Deutschland Gmbh Heterocyclylessigsäuren als Inhibitoren von TAFla
NZ577312A (en) 2006-12-06 2012-02-24 Sanofi Aventis Urea and sulfamide derivatives as tafia inhibitors
JP5531011B2 (ja) 2008-06-06 2014-06-25 サノフイ ＴＡＦＩａの阻害剤としての大環状尿素およびスルファミド誘導体

Also Published As

Publication number Publication date
PL2300462T3 (pl) 2014-10-31
DOP2010000363A (es) 2010-12-15
CO6321271A2 (es) 2011-09-20
IL209772A (en) 2016-04-21
IL209772A0 (en) 2011-02-28
ZA201007719B (en) 2011-07-27
US9309207B2 (en) 2016-04-12
AR072007A1 (es) 2010-07-28
PT2300462E (pt) 2014-08-05
CA2726554C (en) 2015-02-24
TW201008917A (en) 2010-03-01
HRP20140787T1 (hr) 2014-11-21
CN102056922A (zh) 2011-05-11
KR101673886B1 (ko) 2016-11-08
NI201000203A (es) 2011-09-29
UA104002C2 (ru) 2013-12-25
US20160251324A1 (en) 2016-09-01
HN2010002558A (es) 2012-08-28
NZ589671A (en) 2012-03-30
JP2011521981A (ja) 2011-07-28
HK1152936A1 (en) 2012-03-16
UY31868A (es) 2010-01-05
US20160024033A1 (en) 2016-01-28
US9688645B2 (en) 2017-06-27
BRPI0913349A2 (pt) 2015-11-24
US9126955B2 (en) 2015-09-08
KR20110020795A (ko) 2011-03-03
JP5531011B2 (ja) 2014-06-25
RU2010154089A (ru) 2012-07-20
US8722655B2 (en) 2014-05-13
CA2726554A1 (en) 2009-12-10
WO2009146802A1 (de) 2009-12-10
EP2300462A1 (de) 2011-03-30
CR11807A (es) 2011-02-16
US20140206760A1 (en) 2014-07-24
DK2300462T3 (da) 2014-08-18
MX2010012793A (es) 2010-12-14
MA32322B1 (fr) 2011-05-02
US20110178130A1 (en) 2011-07-21
TWI455928B (zh) 2014-10-11
SI2300462T1 (sl) 2014-09-30
ECSP10010655A (es) 2011-01-31
SV2010003747A (es) 2011-03-15
RU2502736C2 (ru) 2013-12-27
US8580777B2 (en) 2013-11-12
CL2009001358A1 (es) 2009-11-27
US20140039011A1 (en) 2014-02-06
EP2300462B1 (de) 2014-05-21
ES2494390T3 (es) 2014-09-15
AU2009254257B2 (en) 2013-11-21
CN102056922B (zh) 2013-11-20
AU2009254257A1 (en) 2009-12-10

Similar Documents

Publication Publication Date Title
CY1115604T1 (el) Μακροκυκλικα παραγωγα ουριας και σουλφαμιδης ως αναστολεις των ταfια
CY1120318T1 (el) Υποκατεστημενες βενζυλινδαζολες για χρηση ως αναστολεις κινασης bub1 στη θεραπευτικη αντιμετωπιση υπερπολλαπλασιαστικων ασθενειων
CY1118143T1 (el) Ετεροκυκλικες ενωσεις χρησιμες ως αναστολεις της pdk1
DK1853602T3 (da) Kemiske forbindelser
DK1853588T3 (da) Kemiske forbindelser
UA107783C2 (en) Isoindoline compounds for use in treating cancer
EA201170521A1 (ru) Новые соединения
UA104137C2 (ru) Пиридилсодержащие ингибиторы передачи сигнала через белок hedgehog
NO20082594L (no) Pyrimidinylbenzotiofenforbindelser
EA201100311A1 (ru) Амидные производные гетероарилов и их применение в качестве активаторов глюкокиназы
CY1108087T1 (el) ΠΑΡΑΓΩΓΑ ΙΜΙΔΑΖΟΛΙΟΥ ΩΣ ΑΝΑΣΤΟΛΕΙΣ ΤΟΥ TAFIa
WO2008103277A3 (en) Nitrogen-containing heterocyclyl ketones and their use as c-met inhibitors
EA201390609A1 (ru) ПРОИЗВОДНЫЕ ГИДАНТОИНА, ПОЛЕЗНЫЕ В КАЧЕСТВЕ ИНГИБИТОРОВ Kv3-КАНАЛОВ
CY1112497T1 (el) Παραγωγα διοξα-δικυκλο[3.2.1]οκταν-2,3,4-τριολης
EA201200323A1 (ru) Соединения и композиции, как ингибиторы протеинкиназы
MA33894B1 (fr) Procedes d'administration therapeutique de la pirferidone
SG178952A1 (en) Chemical compounds
EA200801428A1 (ru) Производные пиридиазинона для лечения опухолей
EA201171367A1 (ru) Винилиндазолильные соединения
EA201170531A1 (ru) Соединения на основе пиридина и пиримидина в качестве ингибиторов сигнального пути wnt для лечения рака
EA201170252A1 (ru) Амидофеноксиндазолы в качестве ингибиторов c-мет
EA201270049A1 (ru) Дизамещенные фталазиновые антагонисты пути hedgehog
EA200971068A1 (ru) Триазолиламинопиримидиновые соединения
ECSP088749A (es) Compuestos de tetrahidropiridotienopirimidina y procedimientos de uso de los mismos
EA201101477A1 (ru) Органические соединения и их применение